Eton Pharmaceuticals (ETON) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Adjusted EPS
- $0.43
- Estimate
- $0.19
- Surprise
- +126.3%
- Revenue (period 2026-06-30)
- $37.6M
- Score at report (before → after)
- 5.9 → 5.8/10
Revenue source: xbrl.
How the report landed
Eton Pharmaceuticals (ETON) beat the $0.19 estimate with adjusted EPS of $0.43 — a large 126.3% upside surprise. TrendMatrix's engine moved from Hold (5.9/10) to Sell at 5.8/10 after the report — the engine's score fell despite the beat.
Where TrendMatrix's rating stands now
TrendMatrix currently rates ETON Hold at 6.2/10.
0 of the last 4 quarters beat the estimate; this quarter's +126.3% surprise compares with a -40.0% four-quarter average. Next scheduled report: 2026-11-12.
What supports the rating
- High-quality business
- Strong growth profile
What argues against it
- Consecutive earnings misses (2)
- News modifier -1: STRONG_BUY_WAIT → HOLD_IF_HOLDING
- Momentum score 4.3/10 — below 4.5 minimum
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $54.77
- Price target
- $60.35
- Stop
- $50.94
- Upside to target
- +10.2%
- Reward-to-risk
- 0.8:1
The stock trades at 139.0× trailing but 21.6× forward earnings — consensus estimates already build in a substantial earnings recovery.
Model outputs from TrendMatrix’s engine as of 2026-10-07 — shown for context, not personalized investment advice.
ETON at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Drug Manufacturers - Specialty & Generic
- Market cap
- $1.59B
- P/E (fwd)
- 21.6
- P/E (ttm)
- 139.0
- 52-week range
- $14.27–$66.37
- Off 52-week high
- 17.5%
- RSI (14)
- 47
- Volume vs avg
- 0.83×
- Score today
- 6.2/10